Research Keyword: Biomarker testing

Antifungal stewardship in the UK: where are we now?

mycolabadmin

Fungal infections are becoming more common and dangerous because some fungi are developing resistance to antifungal medicines. UK hospitals struggle to manage these infections due to lack of funding, staffing, and limited access to fungal testing services. The paper recommends creating regional fungal expertise centers and setting national standards to improve how antifungal medications are used and monitored across the country.

Read More »

A Pragmatic Strategy for Improving Diagnosis of Invasive Candidiasis in UK and Ireland ICUs

mycolabadmin

Diagnosing invasive candidiasis (a serious fungal infection in ICU patients) is challenging because current blood culture tests are slow and insensitive. This paper presents a practical five-step diagnostic guide for UK and Ireland hospitals that combines risk assessment, biomarker tests, and rapid identification methods to diagnose the infection faster and more accurately. Using this strategy helps doctors avoid unnecessary antifungal drugs while ensuring seriously ill patients receive appropriate treatment quickly, ultimately improving survival rates.

Read More »

Reevaluating the Value of (1,3)-β-D-Glucan for the Diagnosis of Intra-Abdominal Candidiasis in Critically Ill Patients: Current Evidence and Future Directions

mycolabadmin

This review examines how a fungal biomarker called beta-D-glucan (BDG) can help doctors diagnose yeast infections in the abdomens of critically ill patients. While BDG tests in the blood are available, they give many false positives. Testing BDG directly in fluid from the abdomen appears more accurate, especially when combined with blood tests. However, more research is needed before hospitals widely adopt this approach in daily practice.

Read More »
Scroll to Top